Cipla Stock Ne Ki 52-Week High Ko Touch, Q2 Results Se Pehle; Analysts Ne Diya 'Buy' Recommendation

BROKERAGE-REPORTS

Overview

Cipla ka share price ₹1,640.65 ke naye 52-week high par pahunch gaya, positive investor sentiment ke chalte. Pharmaceutical company apni Q2 financial results 30 October ko announce karne wali hai. Kotak Institutional Equities ke analysts steady growth ka anumaan laga rahe hain, jabki Choice Broking ne 'buy' recommendation di hai, strong technicals ka zikr karte hue aur target price ₹1,770–₹1,850 set kiya hai.

Cipla ke stock ne ₹1,640.65 ke 52-week high ko BSE par touch kiya, apne pichhle high ko cross karte hue. Yeh surge company ki 30 October, 2025 ko hone wali board meeting se pehle aaya hai, jahan Q2 ke financial results (September 30, 2025 tak ke quarter aur half-year ke liye) approve kiye jayenge.

Analysts from Kotak Institutional Equities pharmaceutical sector ke liye stable second quarter ki ummeed kar rahe hain, jismein Cipla bhi shamil hai. Unhe US generics pricing mein stability aur export markets mein growth ki apeksha hai. Haalanki, unhone US-focused companies ke liye gRevlimid sales par sequential pricing pressure note kiya hai. Kotak ne Q2 FY26 ke liye Cipla ki domestic sales mein 7% year-over-year growth aur overall 5% year-over-year sales growth project kiya hai.

Choice Broking ne Cipla ke liye 'buy' recommendation di hai, ek constructive technical setup dekhte hue, jismein ascending triangle pattern bhi shamil hai, jo upside breakout ka potential dikhata hai. Ve current levels par ya ₹1,480 ke aas-paas dips par kharidne ki salah dete hain, jiska medium to long-term target range ₹1,770–₹1,850 hai. Stock key Exponential Moving Averages (EMAs) ke upar trade kar raha hai, aur Relative Strength Index (RSI) further upward momentum ke liye room indicate karta hai.

Impact:
Yeh news Cipla ke stock ke liye highly positive hai, jo strong market confidence aur further appreciation ka potential signal karti hai. Upcoming results aur analyst/brokerage outlook sustained performance ke liye crucial honge. Rating: 7/10.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.